Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00856544 · ClinicalTrials.gov registry record · Phase 3

A Study Comparing 2 Doses Of CP-690,550 Vs. Placebo For The Treatment Of Rheumatoid Arthritis In Patients On Other Background Arthritis Medications

A Phase 3 study of Arthritis, Rheumatoid, sponsored by Pfizer.

Completed
Registry status
Phase 3
Development phase
795
Enrollment target
20
Study locations

NCT00856544 is a Phase 3 study of Arthritis, Rheumatoid that has completed, run by Pfizer. The registered enrollment target is 795 participants, above the 612-participant average among 27 other Arthritis, Rheumatoid trials with a reported enrollment target (30% higher). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00856544, a Phase 3 study of Arthritis, Rheumatoid, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 3
Development phase
795 participants
Enrollment target
20
Study locations

Study Summary

This Phase 3 study is intended to provide evidence that CP-690,550 dosed 5 mg BID and 10 mg BID is safe and effective when used in combination with a variety of traditional disease modifying antirheumatic drugs in adult patients with rheumatoid arthritis. It is intended to confirm the benefits of CP-690,550 in improving signs and symptoms and physical function that were observed in the Phase 2 rheumatoid arthritis studies.

Conditions Studied

Arthritis, Rheumatoid

Interventions

  • DRUG Placebo
  • DRUG CP-690,550

Study Locations (20)

Florida

  • Pfizer Investigational Site - New Port Richey
  • Pfizer Investigational Site - Ocala
  • Pfizer Investigational Site - Plantation
  • Pfizer Investigational Site - Port Richey
  • Pfizer Investigational Site - Tamarac
  • Pfizer Investigational Site - Tampa

Connecticut

  • Pfizer Investigational Site - Danbury
  • Pfizer Investigational Site - Hamden
  • Pfizer Investigational Site - Trumbull

Illinois

  • Pfizer Investigational Site - Maywood
  • Pfizer Investigational Site - Oakbrook Terrace
  • Pfizer Investigational Site - Rockford

California

  • Pfizer Investigational Site - Palo Alto
  • Pfizer Investigational Site - Stanford

Colorado

  • Pfizer Investigational Site - Boulder
  • Pfizer Investigational Site - Denver

Georgia

  • Pfizer Investigational Site - Decatur
  • Pfizer Investigational Site - Marietta

Alabama

  • Pfizer Investigational Site - Huntsville

Arkansas

  • Pfizer Investigational Site - Jonesboro

Trial Details

FieldValue
Enrollment Target 795 participants
Start Date 2009-05
Est. Completion 2011-01
Phase Phase 3

Sponsor

Pfizer

1,845 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00856544

The ClinicalTrials.gov registry entry for NCT00856544 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 795 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 612-participant average among 27 other Arthritis, Rheumatoid trials with a reported enrollment target (30% higher). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Arthritis, Rheumatoid appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00856544 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Florida, Connecticut, Illinois.

Frequently Asked Questions

What is clinical trial NCT00856544 about?

NCT00856544 is a clinical study titled "A Study Comparing 2 Doses Of CP-690,550 Vs. Placebo For The Treatment Of Rheumatoid Arthritis In Patients On Other Background Arthritis Medications". This Phase 3 study is intended to provide evidence that CP-690,550 dosed 5 mg BID and 10 mg BID is safe and effective when used in combination with a variety of traditional disease modifying antirheumatic drugs in adult patients with rheumatoid arthritis. It is intended to confirm the benefits of CP...

What is the current status of trial NCT00856544?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 795 participants. The study started on 2009-05. Estimated completion is 2011-01.

What conditions does trial NCT00856544 study?

This clinical trial studies the following conditions: Arthritis, Rheumatoid.

What interventions are being tested in trial NCT00856544?

The interventions under investigation include: Placebo (DRUG), CP-690,550 (DRUG).

Who is sponsoring clinical trial NCT00856544?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00856544 being conducted?

This trial has 20 study locations across Alabama, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Arthritis, Rheumatoid

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Arthritis, Rheumatoid

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.